AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 2 approved, 1 approved with reservations]

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 2 approved, 1 approved with reservations]

Background: Dolutegravir has superior efficacy and tolerability than lopinavir-ritonavir in second-line antiretroviral therapy after failure of a first-line non-nucleoside reverse transcriptase inhibitors-based regimen, when dolutegravir is accompanied by at least one fully active nucleoside reverse...

Full description

Bibliographic Details
Main Authors: Zimasa Gcwabe, Kaneez Sayed, Charlotte Schutz, Olina Ngwenya, Eric Goemaere, Rene Goliath, Amanda Jackson, Rulan Griesel, Andrew Hill, Graeme Meintjes, Tali Cassidy, Claire Keene, Ying Zhao, Gary Maartens
Format: Article
Language:English
Published: Wellcome 2021-02-01
Series:Wellcome Open Research
Subjects:
Second-line
antiretroviral therapy
dolutegravir
HIV
randomised controlled trial
eng
Online Access:https://wellcomeopenresearch.org/articles/6-33/v1

Internet

https://wellcomeopenresearch.org/articles/6-33/v1

Similar Items